A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress

Summary & key facts

This is a 2025 review of current studies about psilocybin, the psychedelic compound in Psilocybe mushrooms. The paper summarizes evidence on psilocybin’s possible benefits for major depressive disorder, treatment-resistant depression (TRD), and end-of-life distress, and it discusses safety, dosing, drug interactions, and limits of the research. The review notes clinical interest and regulatory progress (FDA “breakthrough therapy” designations) but also points out legal and evidence gaps that mean more studies are needed.

Key facts:

• Psilocybin is a naturally occurring psychedelic alkaloid found mainly in Psilocybe mushrooms.
• About 300 million people worldwide are estimated to have major depressive disorder (MDD).
• More than 700,000 people die by suicide each year, and suicide is a leading complication of depression mentioned in the review.
• Only about 30–40% of patients with depression achieve full remission with first-line treatment according to the review.
• Around one-third of people with depression do not respond even after trying four different antidepressants, a situation often called treatment-resistant depression (TRD).
• SSRIs (a common first-line antidepressant) do not work for 30–50% of patients, per the review’s summary of prior evidence.
• Psilocybin has regained clinical research attention since about 2000, and in 2018–2019 the FDA gave “breakthrough therapy” status to psilocybin programs for TRD and MDD from Compass Pathways and the Usona Institute.
• The review covers psilocybin’s reported efficacy, safety profile, possible indications and contraindications, drug-drug interactions, adverse reactions, pharmacokinetics, pharmacodynamics, and dosing regimens, but it emphasizes remaining re

Abstract

The purpose of this review is to provide a comprehensive overview of the current findings and data on the therapeutic effects of psilocybin, a naturally occurring psychedelic alkaloid primarily found in Psilocybe mushrooms. This review covers psilocybin's efficacy and safety profile, therapeutic effects, proposed indications and contraindications, drug-drug interactions, adverse reactions, pharmacokinetics, pharmacodynamics, and dosing regimens as treatment guidelines. The goal is to offer a consolidated resource containing the essential pharmaceutical information on psilocybin currently available.

Topics

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies

Categories

Clinical Psychology Psychology Social Sciences

Tags

Adverse effect Clinical psychology Depression (economics) Distress Dosing Drug Economics Hallucinogen Intensive care medicine Macroeconomics Medicine Pharmacodynamics Pharmacokinetics Pharmacology Psilocybin Psychiatry

Substances

Psilocybin

Conditions & symptoms

Anxiety Depression Anxiety or worry Sadness or low mood